Phospholipase A 2 s (PLA 2 s) 1 are a family of enzymes that hydrolyze the sn-2 position of the ester bond in glycerophospholipids, releasing free fatty acids and lysophospholipids. In turn, the released free fatty acids, especially arachidonic acid, are converted to bioactive lipid mediators such as prostaglandins (PGs) and leukotrienes through the cyclooxygenase (COX) and lipoxygenase (LOX) pathways, respectively (1) (2) (3) (4) (5) (6) (7) . To date, a number of mammalian intracellular and secretory PLA 2 s (sPLA 2 ) have been identified, and some of them, including group IVA cytosolic PLA 2 (cPLA 2 ␣) and several sPLA 2 s, can be functionally coupled with the COX or LOX pathways for the stimulus-induced production of bioactive eicosanoids (1, 8 -10) .
Among the sPLA 2 s, group IIA sPLA 2 (sPLA 2 -IIA) is a prototypic proinflammatory sPLA 2 that is found to be highly elevated both in the circulation and locally in the tissue in association with a variety of pathological conditions such as rheumatoid arthritis, sepsis, and atherosclerosis (11) (12) (13) . Consequently, it is thought that sPLA 2 -IIA participates in the progression of proinflammatory reactions. The expression of sPLA 2 -IIA is inducible in a wide variety of cells and tissues following various stimuli, such as interleukin (IL)-1␤, IL-6, tumor necrosis factor-␣ (TNF␣), lipopolysaccharide, interferon-␥, phorbol esters, and cAMP-elevating agents. Consistent with this marked inducibility, the promoter region of the sPLA 2 -IIA gene contains TATA and CAAT boxes as well as several elements homologous with consensus sequences for binding of stimulus-activated transcription factors, such as C/EBPs, cAMP-response element-binding protein, NF-B, STAT, and AP-1 (14 -16) . In contrast, stimulus-induced sPLA 2 -IIA expression has been shown to be negatively regulated by anti-inflammatory cytokines or growth factors, such as transforming growth factor-␤ (TGF-␤), insulin-like growth factor-1, and platelet-derived growth factor (PDGF) (17) (18) (19) . Thus, the molecular mechanisms underlying the regulation of sPLA 2 -IIA expression appear to be diverse, and the mechanisms for the induction or repression of sPLA 2 -IIA expression by particular stimuli differ according to cell type and even animal species.
Our current studies have demonstrated that stimulation of rat fibroblastic 3Y1 cells with IL-1␤ and TNF␣ synergistically induces the expression of sPLA 2 -IIA, leading to delayed PGE 2 biosynthesis in cooperation with inducible COX-2 (20) . In this system, the expression of sPLA 2 -IIA is sensitive to inhibitors of cPLA 2 and LOX and conversely is enhanced by overexpression of 12/15-LOX, the only LOX isozyme that is endogenously detectable in 3Y1 cells (20 -22) . Furthermore, suppression of sPLA 2 -IIA expression by the cPLA 2 inhibitor could be restored by certain lipid products of the cPLA 2 ␣-12/15-LOX pathway (22) . Although these observations suggest that the expression of sPLA 2 -IIA depends on prior activation of the cPLA 2 -12/15-LOX pathway in these cells, and the requirement for cPLA 2 ␣ and/or 12/15-LOX for sPLA 2 expression has also been demonstrated in several, even if not all, cellular systems (23), the precise underlying machinery for this regulatory pathway and its physiological relevance are not yet fully understood.
In the present study, we found that IL-1␤/TNF␣-stimulated induction of sPLA 2 -IIA mRNA requires prior induction of certain regulatory proteins, expression of which depends on the cPLA 2 -12/15-LOX pathway. In search of such factors, we identified macrophage inflammatory protein (MIP)-2, a CXC chemokine, as a critical intermediate regulator of IL-1␤/TNF␣-dependent, 12/15-LOX-regulated induction of sPLA 2 -IIA. Additionally, we provide evidence that the transcription factor AP-1 contributes to the positive regulation of sPLA 2 -IIA transcription and that signaling by TGF-␤ and PDGF contributes to its negative regulation.
EXPERIMENTAL PROCEDURES
Materials-Mouse IL-1␤, human TNF␣, and human PDGF-BB were purchased from Genzyme. Nordihydroguaiaretic acid (NDGA), a LOX inhibitor, was purchased from BioMol. Cycloheximide (CHX) was purchased from Wako Chemicals. Arachidonyl trifluoromethyl ketone (AA-COCF 3 ), a cPLA 2 inhibitor, and the enzyme immunoassay kit for PGE 2 were obtained from Cayman Chemicals. Rat MIP-2, N(G)-monomethyl-L-arginine (L-NMMA), and polyclonal antibody against human PDGF-BB were purchased from Sigma. Human TGF-␤1 and monoclonal antibody against TGF-␤1, -2, and -3 were from R & D Systems. Monoclonal antibody against human cPLA 2 ␣ and polyclonal antibodies against mouse IL-8RA (CXCR-1) and mouse IL-8B (CXCR-2) were purchased from Santa Cruz Biotechnology. Polyclonal antibody against rat MIP-2 was purchased from PeproTech. The cDNAs for rat sPLA 2 -IIA (24) and mouse cPLA 2 ␣-(1-522) (25) were prepared as described previously. Lipofectamine 2000, Oligofectamine, Opti-MEM medium, TRIzol reagent, geneticin, hygromycin, and the pcDNA3.1 series of mammalian expression vectors were obtained from Invitrogen. 3Y1 cells were generously given by Dr. Y. Uehara (National Institute of Infectious Disease) and were maintained in culture medium composed of Dulbecco's modified Eagle's medium (DMEM; Nissui Pharmaceutical) supplemented with 10% (v/v) fetal calf serum (FCS), penicillin/streptomycin (100 units/ml and 100 g/ml, respectively), and 2 mM glutamine (Invitrogen) at 37°C in a CO 2 incubator flushed with 5% CO 2 in humidified air. 3Y1 cells stably expressing 12/15-LOX were described previously (21) .
Activation of 3Y1 Cells-The media of 3Y1 cells that had attained 80% confluence in 6-well plates (Iwaki Glass) were replaced with 2 ml of DMEM supplemented with 2% FCS. After culture for 24 h, 1 ng/ml mouse IL-1␤ and 2 ng/ml human TNF␣ or various concentrations of rat MIP-2 were added to the cultures. In other sets of experiments, 3Y1 cells were pretreated with various concentrations of rat PDGF-BB, rat TGF-␤1, or their antibodies for 3 h and then treated with IL-1␤/TNF␣ for 24 h. For RNA blotting, TRIzol reagent was added directly to the cell monolayer.
cDNA Array Analysis-mRNAs isolated from mock-and 12/15-LOXtransfected 3Y1 cells (10 7 cells for each) were reverse-transcribed into cDNA and 32 P-labeled with an Atlas cDNA expression arrays kit (Clontech). Hybridization was performed on the Atlas Rat 1.2 array kit (Clontech). After exposure to an image plate (BAS III; Fuji Photo Film), signals were analyzed with AtlasImage 1.0 software (Clontech).
Reverse Transcriptase (RT)-PCR-Synthesis of cDNA was performed with 1 g of total RNA and avian myeloblastosis virus-reverse transcriptase according to the manufacturer's instructions supplied with the RNA PCR kit (avian myeloblastosis virus, version 2.1; Takara Biomedicals). Subsequent amplifications of the partial cDNA were performed using 0.5 l of the reverse-transcribed mixture as a template with specific oligonucleotide primers (Sigma) as follows: rat MIP-2, sense 5Ј-TTT GGT CCA GAG CCA TGG CC-3Ј and antisense 5Ј-CCA  GGT CAG TTA GCC TTG CC-3Ј; rat c-JUN, sense 5Ј-CGC GTG AAG  TGA CCG ACT GT-3Ј and antisense 5Ј-TGA GGT TGG CGT AGA CCG  GA-3Ј; rat FRA-1, sense 5Ј-CAT GTA CCG AGA CTT CGG GG-3Ј and  antisense 5Ј-GCC TCA CAA AGC CAG GAG TG-3Ј; rat inducible nitricoxide synthase (iNOS), sense 5Ј-GCA CAT GCA GAA TGA GTA CC-3Ј  and antisense 5Ј-GTC TGG CGA AGA ACA ATC C-3Ј; rat fatty acidbinding protein (FABP)-5, sense 5Ј-CAT GGC CAG CCT TAA GGA  CC-3Ј and antisense 5Ј-CTG CTG TCC AGG ATG ACG AG-3Ј; rat  adipocyte FABP (A-FABP), sense 5Ј-ATG TGT GAT GCC TTT GTG  GGG-3Ј and antisense 5Ј-TTA TGC TCT TTC ATA AAC TCT TGT A-3Ј;  rat IL-6, sense 5Ј-GCC CAC CAG GAA CGA AAG TC-3Ј and antisense  5Ј-ACT AGG TTT GCC GAG TAG ACC-3Ј; rat platelet-activating factor  receptor (PAF-R), sense 5Ј-CTG CCC AGA GCA ATG GAG CA-3Ј and  antisense 5Ј-GAA GGC TCT GGA CCT GGC TT-3Ј, rat PDGF receptor  ␣ chain (PDGFR␣), sense 5Ј-CAG AAT ACT GCT TCT ATG GG-3Ј and  antisense 5Ј-GAT GAA AGT GGA ACT ACT GG-3Ј; rat TGF-␤ receptor  type II (TGF-␤RII), sense 5Ј-ACG ACC CCA AGT TCA CCT AC-3Ј and  antisense 5Ј-GGC CAT GTA TCT CGC TGT TC-3Ј; rat CXCR1, sense  5Ј-AGG GTT CCA ATG ACC AAC AGG3Ј and antisense 5Ј-AGA CGT  GCG AAA GGA AGC AG-3Ј ; rat CXCR2, sense 5Ј-ATC AAC AGG TAT GCT GTG GTT G-3Ј and antisense 5Ј-CAG GTC TCC TTG ATC AGC TTG-3Ј; and rat glyceraldehyde 3-phosphate dehydrogenase (GAPDH), sense 5Ј-ATG GTG AAG GTC GGT GTG AAC G-3Ј and antisense 5Ј-TTA CTC CTT GGA GGC CAT GTA G-3Ј. The PCR mixtures were subjected to 35 cycles of amplification by denaturation (30 s at 94°C), annealing (30 s at 60°C), and elongation (1 min at 72°C). The PCR products were analyzed by 1% agarose gel electrophoresis with ethidium bromide.
RNA Blot Analysis-All of the blotting procedures were performed as described previously (20) . Briefly, equal amounts (10 g) of total RNA were applied to each lane of 1.2% (w/v) formaldehyde-agarose gels, electrophoresed, and then transferred to Immobilon-N membranes (Millipore). The resulting blots were then probed with cDNA inserts and labeled with [ 32 P]dCTP (PerkinElmer Life Sciences) by random priming (Takara Biomedicals). Hybridization was carried out at 42°C overnight in a solution comprising 50% (v/v) formamide, 0.75 M NaCl, 75 mM sodium citrate, 0.1% (w/v) SDS, 1 mM EDTA, 10 mM sodium phosphate, pH 6.8, 5ϫ Denhardt's solution (Nakalai Tesque), 10% (w/v) dextran sulfate (Sigma), and 100 g/ml salmon sperm DNA (Wako). The membranes were washed three times at room temperature with 150 mM NaCl, 15 mM sodium citrate, 1 mM EDTA, 0.1% SDS, and 10 mM sodium phosphate, pH 6.8, for 5 min each, followed by two washes at 55°C with 30 mM NaCl, 3 mM sodium citrate, 1 mM EDTA, 1% SDS, and 10 mM sodium phosphate, pH 6.8, for 15 min each. The blots were visualized by autoradiography with Kodak X-Omat AR films and double-intensifying screens at Ϫ80°C.
Transfection of Antisense Oligonucleotide for MIP-2-The antisense (5Ј-TGG CGA GTG GGA GGG GCC AT-3Ј) and sense (5Ј-ATG GCC CTC CCA CTC GCC CA-3Ј) oligonucleotides, which correspond to the translation initiation site for rat MIP-2, were each incubated at 200 nM with Oligofectamine reagent in 200 l of Opti-MEM for 15 min at room temperature and then added to cells that had attained 60 -80% confluence in 6-well plates and had been supplemented with 800 l of Opti-MEM. After incubation for 6 h at 37°C, the medium was replaced with 2 ml of DMEM supplemented with 2% FCS in the continued presence of 200 nM oligonucleotide. After culture for 24 h, 1 ng/ml IL-1␤ and 2 ng/ml TNF␣ were added to the culture to activate the cells.
Establishment of MIP-2 Small Interfering RNA (siRNA)-expressing Cells-The target sequences for MIP-2 siRNA were subcloned into pRNA-U6.1/Hygro (GenScript Corporation) at the HindIII/BamHI sites. The sense sequences of the synthesized oligonucleotides (BEX) used were as follows: 5Ј-GAT CCC GAA CAT CCA GAG CTT GAC GTT CAA GAG ACG TCA AGC TCT GGA TGT TCT TTT TTG GAA A-3Ј and 5Ј-GAT CCC GCC CCC TTG GTT CAG AGG ATT CAA GAG ATC CTC TGA ACC AAG GGG GCT TTT TTG GAA A-3Ј. The plasmids were transfected into 3Y1 cells with Lipofectamine 2000 according to the manufacturer's instructions. Three days after transfection, the cells were seeded into 96-well plates in the presence of 100 g/ml hygromycin in order to establish stable transfectants. The IL-1␤/TNF␣-dependent expression levels of MIP-2 in the obtained transfectants were assessed by RNA blotting and immunoblotting.
Establishment of cPLA 2 ␣-(1-522)-expressing Cells-The cDNA for cPLA 2 ␣-(1-522), which had been subcloned into pcDNA3.1/Hygro, was transfected into 3Y1 cells with Lipofectamine 2000 according to the manufacturer's instructions. Three days after transfection, the cells were seeded into 96-well plates in the presence of 100 g/ml hygromycin in order to establish stable transformants expressing cPLA 2 ␣-(1-522). The expression levels of cPLA 2 ␣-(1-522) in the obtained transfectants were assessed by immunoblotting. To assess immediate and delayed PGE 2 biosynthesis in these transfectants, the cells were activated with 1 M A23187 for 10 min and IL-1␤/TNF␣ for 24 h, respectively, and the amounts of PGE 2 released into the supernatant were measured.
Immunoblot Analysis-Cell lysates (10 5 cells equivalent) were subjected to SDS-PAGE using 10 or 15% (w/v) gels under reducing conditions. The separated proteins were electroblotted onto nitrocellulose membranes (Schleicher & Schuell) with a semidry blotter (Bio-Rad) according to the manufacturer's instructions. After blocking for 2 h with 3% (w/v) skimmed milk in 10 mM Tris-HCl, pH 7.4, containing 150 mM NaCl and 0.05% Tween 20 (TBS-Tween), the membranes were probed for 2 h with the respective antibodies (1:5,000 for MIP-2, CXCR-2, and CXCR-1; 1:2,000 for cPLA 2 ␣), followed by incubation with horseradish peroxidase-conjugated anti-mouse (for cPLA 2 ␣), anti-rabbit (for MIP-2 and CXCR2), or anti-goat (for CXCR1) IgG (1:10,000 dilution in TBSTween). After washing, the membranes were visualized with Western Lightning Chemiluminescence Reagent Plus (PerkinElmer Life Sciences), as described previously (26) .
Electrophoretic Mobility Shift Assay (EMSA)-Double-stranded oligonucleotides containing the consensus sequences for the binding sites for AP-1 and peroxisome proliferator-response element (PPRE) in the promoter region of the rat sPLA 2 -IIA gene were radiolabeled with [␣- 32 P]dCTP at their 3Ј ends with a Klenow fragment (Takara Biomedicals) and then purified with a Micro Bio-Spin 6 chromatography column (Bio-Rad). The sense sequences of the synthesized oligonucleotides used were as follows: IIA-AP-1, 5Ј-GAA TGA ATG ACT GAC ACG TG-3Ј; IIA-AP-1 mutant, 5Ј-GAA TGA ATA GTC GAC ACG TG-3Ј (mutated sequence underlined); and IIA-PPRE (34), 5Ј-CAG CTG TTG GGG GGA AAA GGG GA-3Ј. Nuclear extracts of the cells were prepared as described previously (27) . Briefly, the cells were suspended in 10 mM HEPES, pH 7.9, containing 10 mM KCl, 0.1 mM EGTA, 1 mM dithiothreitol (DTT), 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 2 g/ml leupeptin, 2 g/ml pepstatin, and 2 g/ml aprotinin and were incubated for 10 min on ice. Nonidet P-40 was added to the suspension at a final concentration of 0.4% (v/v), and the mixtures were vortex-mixed vigorously for 10 s; the nuclei were then pelleted by centrifugation at 15,000 ϫ g for 1 min. The pellets were resuspended in 20 mM HEPES, pH 7.9, containing 0.4 M NaCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 M PMSF, 2 g/ml leupeptin, 2 g/ml pepstatin, and 2 g/ml aprotinin by vigorous mixing for 5 min at 4°C. After centrifugation at 10,000 ϫ g for 5 min, the supernatants were used as nuclear extracts. The nuclear extracts were incubated with 1 ng of radiolabeled AP-1 or PPRE oligonucleotide in binding buffer (10 mM HEPES, pH 7.9, containing 50 mM KCl, 5 mM MgCl 2 , 0.5 mM EDTA, 5 mM DTT, 0.7 mM PMSF, 2 g/ml leupeptin, 2 g/ml pepstatin, 2 g/ml aprotinin, 10% (v/v) glycerol, and 1 g/ml poly(dI-dC)⅐poly(dI-dC)) for 30 min at 25°C. For competition assay, a 50-fold excess of unlabeled oligonucleotide was added to the binding reaction prior to the addition of the radiolabeled probe. These incubation mixtures were electrophoresed in 4.5% native polyacrylamide gels with Tris borate-EDTA buffer, pH 8.8. The gels were dried and analyzed with a BAS2000 (Fuji Photo Film).
RESULTS

sPLA 2 -IIA mRNA Expression in IL-1␤/TNF␣-treated 3Y1 Cells Requires de Novo Protein Synthesis-
We have shown previously that delayed PGE 2 generation induced by IL-1␤ and TNF␣ in 3Y1 cells is regulated by functional coupling between two inducible enzymes, sPLA 2 -IIA and COX-2, and that the induction of sPLA 2 -IIA, but not COX-2, is suppressed by cPLA 2 and LOX inhibitors at the transcriptional level (20) . Conversely, when 3Y1 cells overexpressing 12/15-LOX (a LOX isozyme expressed in 3Y1 cells (21)) were cultured with IL-1␤/ TNF␣ for 24 h, the expression levels of sPLA 2 -IIA, but not COX-2, mRNA ( Fig. 1, 2nd and 5th lanes) and protein (21) were markedly up-regulated relative to that in replicate mock-transfected cells. In addition to these observations, we found herein that de novo protein synthesis was required for full induction of sPLA 2 -IIA, but not COX-2, mRNA, because adding CHX, a protein synthesis inhibitor, to 3Y1 cells greatly decreased the amount of IL-1␤/TNF␣-induced sPLA 2 -IIA mRNA in mock-and 12/15-LOX-transfected cells (Fig. 1, lanes 3 and 6) . Appropriate expression of 12/15-LOX in the transfectants was confirmed by its enzymatic activity and mRNA expression, as described previously (21) . Based on these results, we hypothesized that stimulation by IL-1␤/TNF␣ induces certain regulatory factor(s), which in turn amplify the expression of sPLA 2 -IIA in a manner dependent upon the product(s) of the cPLA 2 -12/15-LOX pathway.
Identification of 12/15-LOX-regulated Genes-
In an attempt to identify such factor(s) that intermediate the cytokine-and cPLA 2 -12/15-LOX-mediated induction of sPLA 2 -IIA, we performed cDNA array analysis to select a panel of genes in which expression was significantly altered in IL-1␤/TNF␣-treated 12/ 15-LOX-overexpressing 3Y1 cells relative to that in replicate mock-transfected cells. As summarized in Table I , increased genes included those required for the inflammatory response (e.g. the CXC chemokine MIP-2, several proinflammatory cytokines such as IL-6, and iNOS), gene transcription (e.g. junD, fra-1, and c-jun), and material transport (e.g. A-FABP and FABP-5). Conversely, decreased genes included receptors for several growth factors (e.g. PDGFR␣ and insulin-like growth factor II receptor) and for anti-inflammatory cytokines (e.g. TGF-␤RII) and annexins (which can inhibit the PLA 2 reaction through substrate depletion (28)).
To assess the IL-1␤/TNF␣-stimulated inducibility of the molecules identified by the cDNA array (Table I) and to ascertain whether the expression levels of these molecules were indeed altered following 12/15-LOX expression, we compared by using high sensitivity RT-PCR and RNA blotting their expression levels in mock-transfected and 12/15-LOX-expressing 3Y1 cells after culture with or without IL-1␤/TNF␣ for 24 h. Examples of RT-PCR for several genes are shown in Fig. 2 , where the expression levels of MIP-2, c-jun, fra-1, iNOS, PAF-R, FABP-5, and A-FABP were significantly higher in 12/15-LOX-transfected cells than in control cells. Elevated expression of MIP-2 and FABPs in 12/15-LOX-expressing cells over control cells was particularly evident (Fig. 2) , consistent with the fact that these genes showed the highest inducibility in the cDNA array assay (Table I) . Although the expressions of MIP-2 and iNOS were undetectable without IL-1␤/TNF␣ stimulation, they were markedly increased after IL-1␤/TNF␣ stimulation. Unlike these molecules, the expressions of c-jun and fra-1 were already evident in unstimulated cells and were modestly increased after IL-1␤/TNF␣ stimulation, particularly in 12/15-LOX-expressing cells (Fig. 2) . A similar result was observed with the expression of PAF-R, except that it was detectable in unstimulated cells and was markedly decreased following IL-1␤/TNF␣ stimulation. By contrast, the expression of FABP-5 and A-FABP was minimally affected by IL-1␤/TNF␣ stimulation. Collectively, these results indicate that MIP-2, iNOS, c-jun, and fra-1, which display inducibility by 12/15-LOX and IL-1␤/TNF␣, are potential candidates for the factor(s) that intermediate the cytokine induction of sPLA 2 -IIA.
Cytokine Induction of sPLA 2 -IIA Is Intermediated by MIP-2-To establish whether these inducible factors indeed intermediate the IL-1␤/TNF␣-induced expression of sPLA 2 -IIA, we first investigated MIP-2 because, among the inducible genes identified thus far, its expression was up-regulated most dra- matically following cytokine stimulation and by 12/15-LOX expression (Table I and Fig. 2 ). As shown in Fig. 3A , when mock-transfected or 12/15-LOX-expressing 3Y1 cells were cultured with IL-1␤/TNF␣, the expression of sPLA 2 -IIA mRNA started to increase after culture for 3 h, increased markedly after 6 h, and reached its maximum at a plateau level after 12-24 h. This induction of sPLA 2 -IIA mRNA was accompanied by induction of its protein expression (as assessed by immunoblotting) and enzymatic activity (as assessed by PLA 2 enzyme assay), as reported previously (20) . In comparison, the expression of MIP-2 mRNA appeared as early as 30 min, reached a maximum level by 3 h, and then decreased over 12-24 h. Increased expression of MIP-2 mRNA was followed by that of its protein, which was minimal before stimulation, increased after culture with IL-1␤/TNF␣ for 3-18 h, and tended to decline gradually thereafter (Fig. 3B) . Thus, IL-1␤/TNF␣ stimulation led to transient induction of MIP-2 expression, followed by persistent induction of sPLA 2 -IIA expression. Furthermore, MIP-2 expression was higher in 12/15-LOX-expressing cells than in control cells at each time point, thus correlating with subsequent increased expression of sPLA 2 -IIA in the former cells (Fig. 3A) .
The cytokine inducibility of endogenous MIP-2 prior to that of sPLA 2 -IIA prompted us to examine whether exogenous MIP-2 directly induces expression of sPLA 2 -IIA mRNA. When 3Y1 cells were stimulated with recombinant rat MIP-2 for 12 h, the induction of sPLA 2 -IIA, as well as that of endogenous MIP-2, occurred in a dose-dependent manner (Fig. 4A ). As shown in Fig. 4B , the expression of sPLA 2 -IIA induced by recombinant MIP-2 became obvious by 3 h, reached its maximum at a plateau level after 6 -12 h, and declined by 24 h. Thus, induction of sPLA 2 -IIA by MIP-2 (ϳ3-6 h) occurs kinetically earlier than that by IL-1␤/TNF␣ (Ͼ6 h; see Fig. 3 ), in line with the hypothesis that IL-1␤/TNF␣ induces MIP-2, which in turn facilitates sPLA 2 -IIA expression. Because several members of the CXC chemokine family, to which MIP-2 belongs, exert their bioactivities through the G protein-coupled receptors CXCR1 and CXCR2 (29 -31), we assessed by RT-PCR and immunoblot analyses the expression of these receptors in 3Y1 cells. Both CXCR1 and CXCR2 mRNAs (Fig. 4C, upper panel) and proteins (Fig. 4C, lower panel) were constitutively expressed in 3Y1 cells, with the former showing a modest increment following IL-1␤/TNF␣ stimulation.
To assess whether the MIP-2 signaling for sPLA 2 -IIA induction requires the cPLA 2 -12/15-LOX pathway, we examined the effects of AACOCF 3 and NDGA on exogenous MIP-2-dependent sPLA 2 -IIA induction. As in the case of IL-1␤/TNF␣ stimulation (Fig. 4D, lanes 6 -9) , the induction of sPLA 2 -IIA mRNA by recombinant MIP-2 was also suppressed by AACOCF 3 or NDGA (Fig. 4D, lanes 3 and 4) , suggesting the involvement of the cPLA 2 -12/15-LOX pathway in this MIP-2-mediated event. By contrast, the addition of CHX, which reduced IL-1␤/TNF␣-dependent sPLA 2 -IIA mRNA induction (Fig. 1) , failed to suppress MIP-2-dependent sPLA 2 -IIA mRNA induction, but rather tended to increase it (Fig. 4D, lane 5) , implying that de novo protein synthesis is not required for MIP-2 signaling leading to sPLA 2 -IIA induction.
To verify further the involvement of cPLA 2 ␣ in IL-1␤/TNF␣-induced MIP-2 expression, cDNA for cPLA 2 ␣-(1-522), a dominant-negative mutant for cPLA 2 ␣ (25), was transfected into 3Y1 cells to establish transfectants stably expressing cPLA 2 ␣-(1-522). Fig. 5A depicts the expression levels of full-length (endogenous) cPLA 2 ␣ and cPLA 2 ␣-(1-522) in cells stably transfected with cPLA 2 ␣-(1-522) and in mock-transfected control cells, as assessed by immunoblotting. The expression of cPLA 2 ␣-(1-522) protein was detected only in cPLA 2 ␣-(1-522) transfectants, whereas the expression levels of endogenous, full-length cPLA 2 ␣ protein were similar in both cell types (Fig.  5A ). When these cells were incubated for 10 min with A23187, which elicits immediate PGE 2 biosynthesis via the cPLA 2 ␣ and COX-1 pathway (20), the expression of cPLA 2 ␣-(1-522) led to ϳ80% reduction of A23187-induced immediate PGE 2 biosynthesis (Fig. 5B, left panel) , confirming the dominant-negative action of cPLA 2 ␣-(1-522) in this situation. As shown in Fig. 4C , when these cells were stimulated for 24 h with IL-1␤/TNF␣, which elicits delayed COX-2-dependent PGE 2 synthesis, significant (even though partial) reduction of sPLA 2 -IIA and MIP-2 expression was observed in cPLA 2 ␣-(1-522) transfectants compared with mock transfectants. In accordance with the partial reduction of sPLA 2 -IIA expression, delayed PGE 2 release was also attenuated by ϳ40% following introduction of cPLA 2 ␣-(1-522) (Fig. 5B, right panel) . These results further support the idea that cytokine induction of MIP-2 (and thereby that of 2) is under the control of cPLA 2 ␣. However, only partial suppression of the delayed response, relative to profound reduction of the immediate response, by cPLA 2 ␣-(1-522) might be indicative of the contribution of additional PLA 2 (s) (possibly other cPLA 2 isozymes) to the delayed response, a possibility that is under investigation.
To obtain more conclusive evidence for the participation of MIP-2 in IL-1␤/TNF␣-induced sPLA 2 -IIA expression, we used antisense and siRNA technologies to specifically reduce MIP-2 expression. As shown in Fig. 6A , transfection of the antisense, but not sense, oligonucleotide for MIP-2 into 3Y1 cells reduced IL-1␤/TNF␣-induced MIP-2 expression (ϳ40% reduction compared with sense oligonucleotide-treated cells; Fig. 6A, lane 3) , with concomitant reduction of IL-1␤/TNF␣-induced sPLA 2 -IIA expression (ϳ20% reduction compared with sense oligonucleotide-treated cells; Fig. 6A, lane 3) . Less sensitivity of sPLA 2 -IIA than MIP-2 to the MIP-2 antisense may be because the residual MIP-2 expression is still capable of inducing sPLA 2 -IIA to some extent or because other proteinaceous factor(s) also participate in sPLA 2 -IIA induction. The antisense oligonucleotide did not suppress the IL-1␤/TNF␣-induced expression of COX-2, implying that the suppression of MIP-2 expression was responsible for selective attenuation of sPLA 2 -IIA expression.
Next, we transfected MIP-2-specific siRNA into 3Y1 cells and examined the expression levels of MIP-2, sPLA 2 -IIA, and cPLA 2 ␣ proteins by immunoblotting. As shown in Fig. 6B , the cytokine-dependent induction of MIP-2 protein in MIP-2 siRNA-transfected cells was markedly reduced (Ͼ80% reduction) compared with that in mock-transfected cells. Accordingly, there was 50 -60% reduction of sPLA 2 -IIA expression in MIP-2 siRNA-treated cells relative to that in control cells at each IL-1␤/TNF␣ concentration employed (Fig. 6B) . Taken together, these results indicate that MIP-2 acts as a positive intermediate regulator for IL-1␤/TNF␣-induced sPLA 2 -IIA expression. Table I and Fig. 2 , 12/15-LOX enhances the expression of c-jun and fra-1, both of which are components of the transcription factor AP-1 (32, 33) . Detailed time course studies of c-jun expression revealed that it was increased only transiently at 30 min after IL-1␤/TNF␣ stimulation in control cells and that its expression levels were higher in 12/15-LOX-transfected cells than in control cells at each time point tested (Fig. 7A) . Furthermore, following the first transient increase at 30 min, there was a second gradual increase in c-jun over 6 -12 h in 12/15-LOX-transfected cells. To assess the contribution of c-JUN to 12/15-LOX-dependent sPLA 2 -IIA expression, we next examined by EMSA the ability of AP-1 to bind to the sPLA 2 -IIA promoter. 12/15-LOX-or mock-transfected 3Y1 cells (Fig. 7B, lanes 5-8 and lanes 1-4, respectively) were treated with or without IL-1␤/TNF␣ for 18 h, and then the nuclear extracts from these cells were subjected to EMSA. As shown in Fig. 7B , constitutive binding of AP-1 to the AP-1-binding motif in the sPLA 2 -IIA promoter (IIA-AP-1 (Ϫ470 to Ϫ480)) was already evident in control cells regardless of the stimulus, and was significantly increased in 12/15-LOX-transfected cells particularly under the IL-1␤/TNF␣-stimulated condition. The specificity of the AP-1 complex was verified by inhibition with an excess of unlabeled IIA-AP-1, but not IIA-AP-1 mutant, oligonucleotide (Fig. 7B, lanes 3, 4, 7, and 8) . In addition, when 3Y1 cells were treated with recombinant MIP-2, the binding of AP-1 to IIA-AP-1 was significantly increased over 3-18 h (Fig. 7C) , indicating that MIP-2-mediated induction of sPLA 2 -IIA also involves AP-1.
12/15-LOX Enhances Binding of AP-1 to Rat sPLA 2 -IIA Promoter-As already shown in
Because PPAR␥ has been reported to play a critical role in the regulation of sPLA 2 -IIA expression in IL-1␤-treated rat vascular smooth muscle cells (34) , and because potential ligands for this transcription factor include 12/15-LOX metabolites (35, 36) , we also tested whether this transcription factor could affect sPLA 2 -IIA transcription, by using the same method. Although binding of PPAR␥ to the sPLA 2 -IIA promoter (Ϫ160 to Ϫ133; a region reported previously to be responsible for the binding to PPAR␥ (34)) was indeed observed in our EMSA, with a trend to increase after IL-1␤/TNF␣ stimulation, it was minimally affected by 12/15-LOX overexpression (Fig.  7D) . The specificity of the PPAR␥ complex was verified by inhibition with an excess of unlabeled oligonucleotide (Fig. 7D,  lanes 3 and 6) . These results suggest that 12/15-LOX increases the basal and IL-1␤/TNF␣-induced expression of AP-1 compo- nents, which leads to enhanced sPLA 2 -IIA transcription, whereas the contribution of PPAR␥ to this 12/15-LOX-regulated event through the reported PPRE site is negligible.
iNOS Is Not Involved in sPLA 2 -IIA Expression-Because nitric oxide has a wide variety of biological functions and one of its biosynthetic enzymes, iNOS, has been implicated in the regulation of eicosanoid synthesis in certain situations (37, 38), we next examined whether iNOS is also involved in IL-1␤/ TNF␣-induced sPLA 2 -IIA expression. When mock-transfected cells were cultured with IL-1␤/TNF␣, the expression of iNOS mRNA, which was undetectable in the basal state, reached a maximum level after 3 h and decreased thereafter over 6 -24 h (Fig. 8A, left panel) . By contrast, the expression of iNOS mRNA was enhanced and prolonged markedly over 3-24 h in replicate 12/15-LOX-transfected cells (Fig. 8A, right panel) , suggesting that 12/15-LOX affects IL-1␤/TNF␣-induced iNOS mRNA expression and/or its stability. However, when 3Y1 cells were cultured with IL-1␤/TNF␣ for 24 h in the presence or absence of L-NMMA, a NOS inhibitor, the induction of sPLA 2 -IIA expression was unaffected in both mock-transfected and 12/15-LOX-expressing cells (Fig. 8B) . No effect of L-NMMA on sPLA 2 -IIA expression was found even at earlier time points (data not shown). These results suggest that, even though augmented induction of iNOS by 12/15-LOX occurs, this event is not functionally linked to the regulation of sPLA 2 -IIA expression.
PDGF and TGF-␤ Signalings Negatively Regulate IL-1␤/ TNF␣-induced sPLA 2 -IIA Expression-As shown in Table I , our cDNA array assay identified the receptors for PDGF and TGF-␤ as 12/15-LOX-down-regulated products. Therefore, we examined by RNA blotting whether the expression levels of these receptors were indeed altered in 12/15-LOX-expressing cells. As shown in Fig. 9A , both PDGFR␣ and TGF-␤RII were expressed constitutively and were modestly increased over 3-24 h of stimulation with IL-1␤/TNF␣ in control cells. The IL-1␤/TNF␣-stimulated expression of PDGFR␣ and TGF-␤RII was markedly decreased in 12/15-LOX-expressing cells compared with that in control cells, and the decreased expression of the former receptor was already evident in unstimulated cells (Fig. 9A) .
When 3Y1 cells were pretreated with PDGF-BB (Fig. 9B ) or TGF-␤ (Fig. 9C) for 3 h and then incubated with IL-1␤/TNF␣ for 24 h in their continued presence, IL-1␤/TNF␣-induced sPLA 2 -IIA mRNA expression was dose-dependently reduced by each of them, with their minimum effects being observed at 10 and 0.1 ng/ml, respectively, suggesting that these factors negatively regulate sPLA 2 -IIA expression. To confirm the contribution of endogenous PDGF and/or TGF-␤ signalings on the regulation of sPLA 2 -IIA expression, we examined the effects of the neutralizing antibodies specific for TGF-␤1 and PDGF-BB on IL-1␤/TNF␣-induced sPLA 2 -IIA expression. The IL-1␤/ TNF␣-mediated induction of sPLA 2 -IIA was significantly increased only by the addition of anti-TGF-␤ antibody but not by that of anti-PDGF-BB and control antibodies (Fig. 9D) . Consistent with this observation, when 3Y1 cells were treated with IL-1␤/TNF␣, endogenous TGF-␤1 mRNA was modestly increased over 1-24 h (Fig. 9E) , whereas no expression of endogenous PDGF-BB mRNA was observed (data not shown). These results suggest that the endogenous TGF-␤ signaling regulates sPLA 2 -IIA induction negatively in 3Y1 cells. 
DISCUSSION
We have shown previously that stimulation by IL-1␤ and TNF␣ causes delayed PGE 2 production in rat fibroblastic 3Y1 cells by promoting the de novo induction of sPLA 2 -IIA and COX-2 at the transcriptional level, and that the expression of sPLA 2 -IIA, but not COX-2, is dependent upon prior activation of cPLA 2 ␣ and its downstream enzyme in another arm of arachidonate metabolism, 12/15-LOX (20 -22) . The results presented in this paper have provided new insights into the regulation of this cPLA 2 ␣-12/15-LOX-dependent expression of sPLA 2 -IIA, as summarized in Fig. 10 . We found that the protein biosynthesis inhibitor CHX suppresses IL-1␤/TNF␣-induced sPLA 2 -IIA mRNA expression, suggesting that de novo induction of certain protein factor(s) is needed for cytokine-and cPLA 2 ␣-12/15-LOX-dependent sPLA 2 -IIA mRNA induction. To identify such factor(s), we used cDNA array analysis to search for genes for which the expression is up-regulated by cytokines and 12/15-LOX overexpression. Of the inducible 12/15-LOXresponsive genes identified thus far, we identified the CXC chemokine MIP-2 as one of the critical mediators of sPLA 2 -IIA induction. Three lines of evidence support this conclusion. First, treatment of 3Y1 cells with IL-1␤/TNF␣ increased MIP-2 expression prior to sPLA 2 -IIA induction, and the expressions of both MIP-2 and sPLA 2 -IIA were markedly enhanced by overexpression of 12/15-LOX. Second, treatment of 3Y1 cells with exogenous MIP-2 induced sPLA 2 -IIA in a time-and dose-dependent manner. Third, suppression of endogenous MIP-2 induction by MIP-2-directed antisense oligonucleotide and siRNA markedly attenuated cytokine-dependent sPLA 2 -IIA expression. This again provides strong support for the notion that MIP-2 functions as an intermediary for regulation of cytokineand cPLA 2 ␣-12/15-LOX-dependent sPLA 2 -IIA expression. We also found that overexpression of 12/15-LOX up-regulates the transcription factor AP-1, which acts as a positive regulator for sPLA 2 -IIA expression, and down-regulates the receptors for TGF-␤ and PDGF, signaling from which negatively regulates sPLA 2 -IIA expression. Thus, 12/15-LOX-dependent induction of sPLA 2 -IIA expression results from the interplay between accelerated MIP-2 expression, AP-1 activation, and attenuated TGF-␤ and PDGF (particularly the former) signaling (Fig. 10) .
Regulation of the Expression of Various Genes by 12/15-LOX-12/15-LOX catalyzes the stereoselective oxidation of arachidonic acid at C12 or C15 and can also directly oxidize esterified fatty acids in lipoproteins and phospholipids membranes (39 -42) . We found that the overexpression of 12/15-LOX affects the expression of various genes, implying that its metabolic product(s) can control their transcription either directly or indirectly. The transcription factor AP-1 is involved in the transcriptional activation of a wide variety of genes (33) . Because the components of AP-1 (c-jun and fra-1) are sensitive to 12/15-LOX, it is possible that some of the 12/15-LOX-induced genes are indirectly regulated by AP-1. Indeed, several 12/15-LOX-responsive genes listed in Table I, Because the products of 12/15-LOX can activate PPARs (35, 36) , some of the 12/15-LOX-induced genes might be regulated by this particular class of nuclear receptors. Indeed, the promoter regions of the genes for some FABPs, including A-FABP, as well as that for sPLA 2 -IIA, contain PPRE elements to which PPARs can bind and thereby transactivate their target genes (34, (43) (44) (45) . Although our present EMSA analysis argues against a requirement for the reported PPAR␥-binding element (Ϫ160 to Ϫ133) in the sPLA 2 -IIA promoter (34) for 12/15-LOXdependent induction of this enzyme, the promoter region may contain additional PPAR-responsive element(s) that could account for PPAR-dependent induction of sPLA 2 -IIA. In fact, we have shown recently that PPAR␣, rather than PPAR␥, may be involved in sPLA 2 -IIA induction in 3Y1 cells (22) . Similarly, PPAR␣ appears to be involved in sPLA 2 -IIA expression in rat mesangial cells (45) .
Mechanisms for MIP-2 Induction of sPLA 2 -IIA-MIP-2, which contains a glutamic acid-leucine-arginine (ELR) sequence immediately preceding the CXC chemokine motif, is a potent neutrophil chemoattractant (46) . In addition to this chemotactic activity, MIP-2 can also activate NF-B (47), a key transcription factor leading to the induction of various proinflammatory genes, which include cytokines (IL-1␤ and TNF␣), iNOS, and COX-2 as well as sPLA 2 -IIA. The expression of MIP-2 has been shown to be increased in macrophages, epithelial cells, and fibroblasts in response to lipopolysaccharide, TNF␣, and oxidative stress (48 -51) . We observed that MIP-2-dependent sPLA 2 -IIA induction is still sensitive to inhibitors of cPLA 2 and LOX, implying that this chemokine-directed event still requires the product(s) of the cPLA 2 ␣-12/15-LOX pathway. In support of this, IL-1␤/TNF␣ treatment increases the expression of MIP-2 mRNA in a time-dependent manner, an event that is enhanced by the overexpression of 12/15-LOX. Moreover, the induction of MIP-2 is markedly attenuated by overexpression of a dominant-negative form of cPLA 2 ␣. Most interestingly, Pawliczak et al. (52) have shown that in epidermal growth factor-and A23187-treated human lung epithelial cell line A549 cells, the stimulus-dependent induction of IL-8, another member of the ELR ϩ CXC chemokine family, is under the control of certain product(s) of the cPLA 2 pathway and that this effect depends partly on PPAR␥ (52) . Thus, even though the precise targets through which cPLA 2 ␣ and 12/15-LOX activate MIP-2 transcription remain to be identified, a possible mechanism for this up-regulation might involve, in part, activation of certain PPARs. Also, although it needs to be clarified which specific intracellular signals produced by the G protein-coupled MIP-2 receptor are able to trigger sPLA 2 -IIA transcription, such signals appear to involve AP-1, because the binding of AP-1 to the sPLA 2 -IIA promoter is significantly elevated following treatment with exogenous MIP-2. We have also shown that stimulation of 3Y1 cells with exogenous MIP-2 induces the expression of endogenous MIP-2. Thus, IL-1␤/TNF␣ signaling, MIP-2 signaling, and the cPLA 2 ␣-12/15-LOX pathway may form a positive amplification relay leading to optimal sPLA 2 -IIA expression (Fig. 10, A and B (17, 19) . Consistent with this, we found that pretreatment of 3Y1 cells with TGF-␤1 or PDGF-BB dose-dependently suppressed IL-1␤/TNF␣-dependent sPLA 2 -IIA induction. Furthermore, we also found that the expression of the receptors for these factors, namely PDGFR-␣ and TGF-␤RII, was markedly up-regulated after IL-1␤/TNF␣ stimulation and that the expression of PDGFR-␣ (constitutive and inducible) and TGF-␤RII (inducible) was markedly attenuated by 12/15-LOX overexpression. These results suggest that certain 12/15-LOX product(s) may down-regulate negative regulatory signals for sPLA 2 -IIA induction, thereby eventually leading to increased expression of sPLA 2 -IIA in 12/15-LOX-expressing cells. Notably, TGF-␤, but not PDGF, is endogenously expressed in 3Y1 cells, and the incubation of the cells with anti-TGF-␤, but not with anti-PDGF, antibody resulted in enhanced IL-1␤/TNF␣-dependent sPLA 2 -IIA induction, suggesting that endogenous TGF-␤, rather than PDGF, signaling may significantly contribute to the regulation of sPLA 2 -IIA expression in our system (Fig. 10C) . Nevertheless, considering the in vivo circumstances, attenuation of sPLA 2 -IIA expression by PDGF or TGF-␤, which could be supplied endogenously or even exogenously from tissue microenvironments at the late stage of inflammation, might contribute, at least in part, to sequestering inflammatory reactions promoted by this proinflammatory enzyme and thus facilitating the tissue repair process promoted by these growth factors.
PGE 2 Generation in 3Y1 Cells-cPLA 2 ␣ is the most important PLA 2 enzyme involved in the production of various eicosanoids as well as lysophospholipid-derived mediators such as PAF (8, 9, 53) . Not only does cPLA 2 ␣ directly supply arachidonic acid to COX and LOX enzymes for the production of eicosanoids, but it also modifies eicosanoid production by sPLA 2 s (54, 55). In some cases, cPLA 2 ␣-derived lipid product(s) appear to regulate the expression of sPLA 2 -IIA and sPLA 2 -V (20, 23). Thus, cPLA 2 ␣ often mediates the stimulus-dependent induction of these sPLA 2 s and subsequent membrane hydrolysis in several cell types (20, 23) , and conversely, sPLA 2 s often induce eicosanoid production by activating cPLA 2 ␣ (56). The synergistic action of cPLA 2 ␣ and sPLA 2 s has been supported further by gene targeting studies as follows: macrophages derived from cPLA 2 ␣ knock-out mice produce eicosanoids only minimally (9), whereas there is also ϳ50% reduction of eicosanoid production in macrophages derived from sPLA 2 -V-deficient mice (57) . In the present study, we showed that overexpression of the dominant-negative form of cPLA 2 ␣ markedly suppressed A23187-induced immediate PGE 2 generation, whereas its suppressive effect on IL-1␤/TNF␣-induced delayed PGE 2 generation was only partial although significant. The latter effect is most likely to be because of suppression of sPLA 2 -IIA induction. These observations thus substantiate our current proposal that the immediate response in 3Y1 cells depends largely on cPLA 2 ␣, whereas the delayed response depends on the concerted action of sPLA 2 -IIA and cPLA 2 ␣. However, generalization of this concept still needs caution, because functional synergism between cPLA 2 ␣ and sPLA 2 s appears to be cell type-specific and stimulus-specific and perhaps in many, even if not all, situations cPLA 2 ␣ is nearly sufficient for eliciting (even delayed) eicosanoid biosynthesis, as has been shown by various cell biological and cPLA 2 ␣ knock-out studies (9, 53) . Thus, efforts to identify specific cell types (like 3Y1 cells) that exhibit sPLA 2 -dependent eicosanoid biosynthesis, particularly in vivo, would be important to shed light on the as yet ambiguous pathophysiological roles of sPLA 2 -IIA and other sPLA 2 family members.
Summary-We have shown here that the induction of sPLA 2 -IIA by proinflammatory cytokines is regulated by complex cross-talk between various signaling pathways, such as up-regulation of chemokine signaling and down-regulation of growth factor signaling, that lie downstream of the product(s) of the cPLA 2 ␣-12/15-LOX pathway. Although identification of the particular bioactive lipid products that dictate this signal amplification cascade will need further study, the development and use of specific inhibitors of the cPLA 2 ␣-12/15-LOX pathway may provide novel approaches to the treatment of inflammatory diseases by attenuating signal pathways involving proinflammatory cytokines, chemokines, and even sPLA 2 s.
